Pharma Focus Asia
KP - Choose our fully recyclable blister films

ELEVIDYS, Novel Gene Therapy Developed for the Tretament of Duchenne Muscular Dystrophy

Sarepta Therapeutics developed a novel gene therapy called ELEVIDYS (delandistrogene moxeparvovec-rokl) for the treatment of ambulatory paediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.

ELEVIDYS, also known as delandistrogene moxeparvovec-rokl, is an innovative gene transfer therapy administered through a single intravenous infusion. It aims to target and address the root cause of Duchenne muscular dystrophy by facilitating the production of ELEVIDYS micro-dystrophin specifically within skeletal muscle tissue. 

To assess its efficacy and safety, ELEVIDYS is currently undergoing evaluation in three ongoing clinical studies known as SRP-9001-101, SRP-9001-102, and SRP-9001-103.

In clinical studies, the most frequently reported adverse reactions were vomiting, nausea, elevated liver function test results, pyrexia (fever), and thrombocytopenia (low platelet count).

U.S. Food and Drug Administration (FDA) grants approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of Duchenne Muscular Dystrophy.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024